Successful Discontinuation of Infliximab in a Refractory Case of Vasculo-Behçet Disease

Reports have shown that antitumor necrosis factor alpha (anti-TNF-α) agents including infliximab (IFX) can dramatically suppress the disease activity of refractory vasculo-Behçet disease (vasculo-BD). However, it is completely unknown whether we can discontinue anti-TNF-α agents under clinical remis...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakamura, Akihiro, Miyamura, Tomoya, Suematsu, Eiichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2016
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4808526/
https://www.ncbi.nlm.nih.gov/pubmed/27034879
http://dx.doi.org/10.1155/2016/1467583

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4808526/
https://www.ncbi.nlm.nih.gov/pubmed/27034879
http://dx.doi.org/10.1155/2016/1467583

Ejemplares similares